This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07219966 |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 1,100 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Alcohol Use Disorder |
| Interventions | LY3537031; Placebo |
| Start | Oct 15, 2025 |
| Primary completion | Apr 2028 |
| Study completion | Apr 2028 |
| Results posted | Not yet |
| Registry last updated | Sep 22, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change in Drinking Patterns in Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method (TLFB) | Up to 56 weeks |
7 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
